Car T Cells for Cancer Therapy

About

Invention Summary: Scientists at NDSU have developed a new device for a scalable, biomanufacturing platform for the production of CAR-modified T-cells while eliminating on-target/off-tumor toxicity and decreasing the current production cost by 500 times (per treatment).  The technology relates to a device to produce modified T-cells comprising a first chamber for proliferating a population of T-cells and a second chamber for modifying the T-cells to express a desired T-cell receptor antigen.  The modified CAR T-cells can be used to treat cancer. Benefits: Expands cells by localizing them with electrical traps  Transfects the cells with desired mRNA using channels, aligning the cells with an electrical field and inserting the mRNA using electrical pulses that produce temporary pores in the cells  Disposable device can be used at the location where the T-cells are drawn, thus avoiding transportation costs and time for production Significantly reduces costs per treatment for cancer patients  Can be automated to allow simultaneous preparation of T-cells for multiple patients Patents: This technology is patent pending with fully preserved PCT patent rights and is available for licensing/partnering opportunities.